Nitto Denko Avecia Inc. (Avecia) announced today the opening of its new oligonucleotide API (active pharmaceutical ingredients) manufacturing facility in Milford, MA. The opening will commence with a ribbon cutting ceremony in August 2017 onsite at the Milford, MA facility. The ceremony will open with remarks from;
- Hideo Takasaki, CEO, Nitto Denko Corporation
- Jay Ash, MA Secretary for the Executive Office of Housing and Economic Development, followed by keynotes from;
- Mark Alles, CEO, Celgene Corporation
- Barry Greene, President, Alnylam Pharmaceuticals
The expansion will add 20,000 square feet of manufacturing and office space at Avecia's Milford, MAsite and provide CGMP oligonucleotide manufacturing capacity up to 1.8mol. The total capacity of Avecia's Milford, MA site has now more than doubled up to 3.0mol, which makes Avecia in Milford, MAthe largest oligonucleotide manufacturing site in the world.
According to Avecia's president Detlef Rethage: "This expansion will help Avecia's clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials as planned. "Avecia takes pride that our engineers have introduced novel technology, executed this expansion in record time, and in close collaboration with A/Z Corporation to ensure the timely supply of novel oligonucleotide therapeutics," said Rethage.
Avecia has added more than 120 MA jobs in the last 12 months in Milford, MA and currently has more than 50 open positions at its four locations in MA, OH, and CA. The new positions will specialize in microbiology, analytical chemistry, manufacturing, quality assurance and engineering. More information on open positions may be found at www.aveciacareers.com.
ABOUT NITTO DENKO AVECIA INC.
Nitto Denko Avecia Inc. is a recognized leader in manufacturing and development services of oligonucleotide therapeutic with facilities located in Milford, MA.; Marlboro, MA.; and Cincinnati OHoffering services for DNA, RNA and other oligonucleotides based therapeutics from milligram scale at pre-clinical stage to 1000kg + post commercial launch. More information: www.Avecia.com. Nitto Denko Avecia is proud member of Nitto Group. More information: www.Nitto.com
ABOUT NITTO AVECIA PHARMA SERVICES INC.
Nitto Avecia Pharma Services is your single solution for premier contract development and manufacturing services. Nitto Avecia Pharma Services supports the pharmaceutical, biopharmaceutical, and medical device industries with a complete package of cGMP services including pre-formulation/formulation, parenteral manufacturing, analytical development, biopharmaceutical development, structural chemistry, analytical chemistry, microbiology, stability storage and drug delivery device testing. With three state-of-the-art facilities located on one campus in Irvine, CA. Learn more at www.aveciapharma.com